Compare F5 Inc (FFIV) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Moderna, Inc. — how do they compare? F5 Inc trades at $460.99 (market cap $26.14B), while Moderna, Inc. trades at $197.17 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 3× F5 Inc's market cap, and F5 Inc is more actively traded (503,146 versus 37,373,437). Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Moderna, Inc. for 59 Days on average.
| FFIV | MRNA | |
|---|---|---|
Market Cap | $26.14B | $78.65B |
Volume | 503,146 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $469.79 | $203.46 |
52-Week Low | $223.99 | $22.36 |
Typical Hold Time | 38 Days | 59 Days |
Enterprise Value | $24.78B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $466.65, down 0.67% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI readings. The company demonstrates robust fundamentals with revenue growth from $2.7B in 2022 to $3.1B in 2025 and expanding net margins reaching 22.42%. Recent recognition as a leader in IDC MarketScape for WAAP platforms and AI security innovations highlight competitive positioning.
FFIV presents a mixed outlook with strong earnings beats and profitability offset by premium valuations (P/E 36.78). Analyst consensus leans cautious with 41% buy ratings and $416.60 price target below current levels. Key risks include competitive pressures in application security and potential valuation compression if growth moderates.
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
